Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

globenewswire

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment – NEWSnet – News… as it used to be

More Press Releases

May 4, 2026

Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market

May 4, 2026

Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations

May 4, 2026

BALTIMORE BUSINESSES INCREASINGLY TURN TO PROFESSIONAL CORPORATE CATERING TO ELEVATE EVENTS

May 4, 2026

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market

Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations

BALTIMORE BUSINESSES INCREASINGLY TURN TO PROFESSIONAL CORPORATE CATERING TO ELEVATE EVENTS

ModusLink Brno Awarded Silver Recognition by the Responsible Business Alliance